96 related articles for article (PubMed ID: 9886723)
1. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition.
Newby DE; McDonagh T; Currie PF; Northridge DB; Boon NA; Dargie HJ
Eur Heart J; 1998 Dec; 19(12):1808-13. PubMed ID: 9886723
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.
Northridge DB; Currie PF; Newby DE; McMurray JJ; Ford M; Boon NA; Dargie HJ
Eur J Heart Fail; 1999 Mar; 1(1):67-72. PubMed ID: 10937982
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
Northridge DB; Newby DE; Rooney E; Norrie J; Dargie HJ
Am Heart J; 1999 Dec; 138(6 Pt 1):1149-57. PubMed ID: 10577447
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure.
Westheim AS; Bostrøm P; Christensen CC; Parikka H; Rykke EO; Toivonen L
J Am Coll Cardiol; 1999 Nov; 34(6):1794-801. PubMed ID: 10577572
[TBL] [Abstract][Full Text] [Related]
5. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
[TBL] [Abstract][Full Text] [Related]
6. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
Kentsch M; Otter W; Drummer C; Nötges A; Gerzer R; Müller-Esch G
Eur J Clin Pharmacol; 1996; 51(3-4):269-72. PubMed ID: 9010697
[TBL] [Abstract][Full Text] [Related]
7. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure.
Kimmelstiel CD; Perrone R; Kilcoyne L; Souhrada J; Udelson J; Smith J; de Bold A; Griffith J; Konstam MA
Cardiology; 1996; 87(1):46-53. PubMed ID: 8631044
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
9. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
O'Connell JE; Jardine AG; Davidson G; Connell JM
J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
[TBL] [Abstract][Full Text] [Related]
10. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.
Elsner D; Müntze A; Kromer EP; Riegger GA
Am J Cardiol; 1992 Aug; 70(4):494-8. PubMed ID: 1386491
[TBL] [Abstract][Full Text] [Related]
12. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
[TBL] [Abstract][Full Text] [Related]
13. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure.
Northridge DB; Rose E; Raftery ED; Lahiri A; Elder AT; Shaw TR; Henderson E; Dargie HJ
Eur Heart J; 1993 Mar; 14(3):403-9. PubMed ID: 8458362
[TBL] [Abstract][Full Text] [Related]
14. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
Richards AM; Wittert GA; Crozier IG; Espiner EA; Yandle TG; Ikram H; Frampton C
J Hypertens; 1993 Apr; 11(4):407-16. PubMed ID: 8390508
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.
Yoshida K; Yasujima M; Casley DJ; Johnston CI
Jpn Circ J; 1998 Sep; 62(9):680-6. PubMed ID: 9766707
[TBL] [Abstract][Full Text] [Related]
16. No effect of the oral neutral endopeptidase inhibitor candoxatril, on bronchomotor tone and histamine reactivity in asthma.
Angus RM; McCallum MJ; Nally JE; Thomson NC
Eur Respir J; 1994 Jun; 7(6):1084-9. PubMed ID: 7925877
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, randomized, placebo-controlled, double-blind study of the safety and efficacy of oral delapril in patients with congestive heart failure.
Circo A; Platania F; Mangiameli S; Putignano E
Am J Cardiol; 1995 Jun; 75(18):18F-24F. PubMed ID: 7778529
[TBL] [Abstract][Full Text] [Related]
18. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers.
Richards AM; Wittert GA; Espiner EA; Yandle TG; Ikram H; Frampton C
Circ Res; 1992 Dec; 71(6):1501-7. PubMed ID: 1423942
[TBL] [Abstract][Full Text] [Related]
19. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides.
McDowell G; Coutie W; Shaw C; Buchanan KD; Struthers AD; Nicholls DP
Br J Clin Pharmacol; 1997 Mar; 43(3):329-32. PubMed ID: 9088591
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
Blanchet M; Sheppard R; Racine N; Ducharme A; Curnier D; Tardif JC; Sirois P; Lamoureux MC; De Champlain J; White M
Am Heart J; 2005 May; 149(5):938.e1-7. PubMed ID: 15894946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
